Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [11] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [11] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [5] - The approval of the every four weeks regimen in Europe is expected to significantly enhance Elfabrio's market uptake [5] Company Strategy and Development Direction - The company aims to advance its clinical pipeline, including PRX-115 and PRX-119, while maintaining a strong financial position to support these initiatives [12] - The company is focused on expanding its renal pipeline and expects to provide updates on specific indications and mechanisms of action in the coming months [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's financial flexibility and growth trajectory, projecting revenue growth in 2026 of greater than 50% [12] - The approval of the every four weeks regimen in Europe is seen as a significant competitive edge, with expectations for accelerated approval in the U.S. [17] Other Important Information - The company anticipates top-line results from the PRX-115 RELEASE study in the second half of 2027 [6] - The company is expanding its renal pipeline through collaborations and new candidates [7] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and sales trajectory in Europe - Management highlighted ongoing promotional activities by Chiesi, including patient ambassador programs, and noted that the approval of the four-week regimen in Europe is expected to enhance market positioning [16] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][20] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal indications and will provide updates on specific mechanisms of action in the future [22][23] Question: Timeline for rollout of Elfabrio's four-week dosing in Europe - Management stated that availability will vary by country, with expectations for rollout starting in the second half of 2026 [27][30] Question: Physician education efforts accompanying the rollout - Management confirmed that Chiesi is actively engaging with treating physicians and stakeholders to promote the new regimen [31]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - As of December 31, 2025, the company held $30.3 million in cash equivalents and short-term bank deposits, with a projected cash balance of approximately $50 million by early April 2026 [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [10] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [10] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [6] - The approval of the every four weeks dosing regimen in Europe is expected to significantly enhance Elfabrio's market position [5] Company Strategy and Development Direction - The company aims to execute its strategy comfortably, including clinical trials, supported by a strong cash position and projected revenue growth [4][12] - The company is advancing its pipeline with PRX-115 for uncontrolled gout and PRX-119 for renal conditions, targeting high unmet needs [6][7] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term trajectory of the Fabry market and the potential for Elfabrio to capture a significant market share [5][12] - The company anticipates a productive 2026, driven by a growing number of patients on Elfabrio and a strong financial position [12] Other Important Information - The European Commission approved the 2 mg/kg every four weeks dosing regimen for Elfabrio, which is expected to enhance long-term management for patients with Fabry disease [3][4] - The company expects to continue increasing R&D investment as its clinical programs advance [9] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. and the impact of the new dosing regimen in Europe - Management highlighted that Chiesi is implementing various promotional activities to increase patient numbers and that the new dosing regimen provides a competitive edge [15][17] Question: Positioning of PRX-115 in the gout market - Management discussed the potential competitive advantages of PRX-115, including improved dosing frequency and safety, and projected a significant market opportunity for uncontrolled gout [18][22] Question: Target indications for PRX-119 and potential commercial opportunities - Management indicated that they are targeting high unmet need renal conditions and will provide updates on specific indications in the future [23][24] Question: Timeline for rollout of the four-week dosing regimen for Elfabrio in Europe - Management stated that the rollout will vary by country, with expectations for effects to start in the second half of 2026 [27][31]

Financial Data and Key Metrics Changes - For the full year 2025, total revenues from selling goods were $51.8 million, a modest decrease compared to 2024, driven by changes in quantities sold to Chiesi's inventory and a change in average net selling price due to increased commercial patients in Europe [8] - The company recorded a net loss of $6.6 million in 2025 compared to a net income of $2.9 million in 2024, reflecting increased investment in the clinical pipeline [10] - Cash equivalents and short-term bank deposits as of December 31, 2025, were $30.3 million, with a projected cash balance of approximately $50 million by early April 2026 due to a $25 million milestone payment [10] Business Line Data and Key Metrics Changes - Revenues from Chiesi are projected to be approximately $33 million-$35 million in 2026, representing growth of more than 50% [11] - Revenues from Elelyso are expected to be approximately $20 million-$23 million in 2026 [11] - Revenues from license and R&D services increased to $0.9 million, mainly related to agreements with Chiesi [8] Market Data and Key Metrics Changes - The Fabry market is projected to reach approximately $3.4 billion by 2030, with Elfabrio's differentiated profile enhancing its competitive positioning [5] - The company anticipates that the approval of the every four weeks regimen in Europe will significantly enhance Elfabrio's market uptake [5] Company Strategy and Development Direction - The company is focused on advancing its clinical pipeline, including PRX-115 for uncontrolled gout and PRX-119 for renal conditions, with expectations of significant market opportunities [5][6] - The company aims to solidify its revenue mix towards Chiesi, which represents the majority of long-term revenue opportunities [8] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in entering 2026 with strong business flexibility and a growing commercial foundation through partners [12] - The projected revenue growth in 2026 of greater than 50% is attributed to the increasing number of patients on Elfabrio [12] Other Important Information - The company is expanding its renal pipeline through collaborations and expects to provide updates on specific indications by the end of Q2 [24] - The approval of the every four weeks regimen in Europe is expected to enhance the competitive edge of Elfabrio [17] Q&A Session Summary Question: Insights on marketing initiatives for Elfabrio in the U.S. - Management noted that Chiesi is implementing various promotional activities, including patient ambassador programs, to increase market uptake [16] Question: Positioning of PRX-115 in the gout market - Management highlighted that PRX-115 could offer significant differentiation in dosing frequency and potential safety advantages, targeting a market expected to exceed $2 billion [20] Question: Timeline for rollout of Elfabrio's four-week dosing in Europe - Management indicated that availability will vary by country, with expectations for some markets to see rollout in the second half of 2026 [30]

Core Viewpoint - Protalix BioTherapeutics is focused on advancing its innovative pipeline for rare diseases, particularly targeting uncontrolled gout and rare kidney diseases, while maintaining a profitable commercial business through strategic partnerships [2][14]. Pipeline and Product Development - The company is advancing PRX-115 for uncontrolled gout, which has shown a rapid and durable urate-lowering effect in Phase 1 trials, indicating its potential as a differentiated treatment option [3][15]. - PRX-119 is being developed as a long-acting DNase I for treating inflammation and fibrosis in rare kidney diseases, reflecting the company's strategic focus on this area [4][13]. - The company has submitted an Investigational New Drug (IND) application for PRX-115, which has been approved by the FDA, and the first clinical sites are now activated [15]. Commercial Execution and Market Positioning - Protalix has achieved solid performance with its partner Chiesi Global Rare Diseases, particularly with the launch of Elfabrio for Fabry disease, tracking well against core indicators such as treated patient counts and market share [6][7]. - The global Fabry market is projected to reach approximately $3.4 billion by 2030, with Protalix expecting Elfabrio to capture 15% to 20% of this market [7]. - An appeal regarding a negative opinion from the European Medicines Agency on Elfabrio's dosing regimen is underway, with an outcome expected in Q1 2026 [8]. Strategic Partnerships and Collaborations - The company continues to benefit from established revenue streams, including Elelyso, through collaborations with Pfizer and Fundação Oswaldo Cruz, which support its operational resilience [9]. - A recent collaboration with Secarna Pharmaceuticals aims to develop novel therapeutic candidates for rare renal indications using AI technology [15]. Long-Term Growth and Value Creation - Protalix enters 2026 with a profitable commercial foundation and a focused pipeline addressing high unmet medical needs, aiming to create long-term value for patients and shareholders [14]. - The company emphasizes its commitment to delivering meaningful therapies while pursuing strategic partnerships to enhance its impact and scale [5][14].

Core Insights - Protalix BioTherapeutics and Secarna Pharmaceuticals have entered into a collaboration and option agreement to develop antisense oligonucleotide therapies for rare renal diseases, leveraging Protalix's expertise in rare diseases and Secarna's AI-powered OligoCreator platform [1][2][3] Company Overview - Protalix BioTherapeutics focuses on innovative therapeutics for rare diseases and has developed two enzyme replacement therapies available in multiple markets, utilizing a proprietary plant cell-based expression system called ProCellEx [4][5] - Secarna Pharmaceuticals specializes in oligonucleotide therapeutics and employs its OligoCreator platform to rapidly generate high-quality antisense candidates, aiming to transform untreatable conditions into treatable ones [7] Collaboration Details - The collaboration involves Protalix selecting pharmaceutical targets for rare renal indications, while Secarna will use its OligoCreator platform to design and profile ASO candidates against these targets [2] - Protalix has the option for an exclusive, worldwide license to further develop and commercialize the therapeutic programs resulting from this collaboration [2][3] Strategic Goals - The partnership aims to advance programs from preclinical stages to clinical trials, addressing significant unmet medical needs in the rare kidney disease space [2][3] - Both companies express excitement about the collaboration, highlighting the combination of Secarna's rapid candidate generation and Protalix's experience in bringing therapies to market [3]

Financial Data and Key Metrics Changes - For the first nine months of 2025, total revenues were $43.6 million, a 24% increase compared to the same period last year [4] - Total revenues for the third quarter were $17.9 million, reflecting a decrease of 1% compared to the same period in 2024 [4] - The net loss for the nine-month period ended September 30, 2025, was $1.1 million, or $0.01 per share, compared to a net loss of $3.6 million, or $0.05 per share for the same period in 2024 [17] - For the three months ended September 30, 2025, net income was approximately $2.4 million, or $0.03 per share, compared to net income of $3.2 million, or $0.04 per share for the same period in 2024 [18] Business Line Data and Key Metrics Changes - Total revenues from selling goods for the nine months ended September 30, 2025, were $43.1 million, an increase of $8.3 million, or 24%, compared to $34.8 million for the same period in 2024 [10] - Revenues consisted of $18.6 million in sales of Elefabrio to Chiesi, $15.4 million in sales of Elelyso to Pfizer, and $9.1 million in sales of Elelyso to Fiocruz in Brazil [10] - For the three months ended September 30, 2025, total revenues from selling goods were $17.7 million, a decrease of $0.1 million, or 1%, compared to $17.8 million for the same period in 2024 [10] Market Data and Key Metrics Changes - The company recognizes revenues from sales to partners, and individual purchases vary from quarter to quarter as each partner controls its own inventories [11] - The company anticipates a significant increase in the overall gout market in the next five to six years, particularly for uncontrolled gout patients requiring uricases [22] Company Strategy and Development Direction - The operating strategy focuses on three pillars: driving commercial success with Elefabrio, advancing PRX-115 and other early-stage pipeline programs, and maintaining financial discipline [7] - The company is preparing for the phase two clinical trial of PRX-115, which is viewed as a strategic investment in the pipeline and long-term growth [13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in Elefabrio's long-term potential and is working closely with Chiesi to support the re-examination of the once-in-four-weeks dosing regimen [6] - The company believes that the achievements in 2025 position it for long-term growth and value creation [19] Other Important Information - Research and development expenses for the nine months ended September 30, 2025, totaled $13.9 million, an increase of 58% compared to the prior year period [13] - Selling general and administrative expenses for the nine months ended September 30, 2025, were $8.2 million, down 11% from the same period last year [14] - The company had $29.4 million in cash and cash equivalents at September 30, 2025, sufficient to satisfy capital needs for at least 12 months [18] Q&A Session Summary Question: Timeline for the re-examination of the CHMP opinion on Elefabrio - The company expects to have an answer in Q1 of 2026 regarding the re-examination request [22] Question: Comments on the competitive landscape in treatment refractory gout - The company foresees a significant increase in the overall gout market and believes that if the phase two trial is successful, it could capture a substantial market share [22] Question: Predictability of royalty-based revenue recognition related to Elefabrio sales - The company continues to recognize what it sells to Chiesi's inventory and is optimistic about future revenue [23][24] Question: Cash runway guidance - The cash runway guidance is based on both operating expenditures and continued receipt of royalty-based revenue on Elefabrio [25][26] Question: Anticipated R&D growth during the phase two of PRX-115 - The company is taking into account the expenses associated with the phase two trial and has sufficient cash for more than 12 months to fund this trial [45]

Company Overview - Protalix BioTherapeutics, Inc. is a New Jersey-based biopharmaceutical company specializing in recombinant therapeutic proteins [4] - The company develops innovative plant-based biologics, including products like Elelyso, Elfabrio, PRX-115, and PRX-119 [4] Investment Activity - Goldman Sachs Group Inc. increased its holdings in Protalix BioTherapeutics by 482.3% during the first quarter, acquiring 239,751 shares, bringing its total ownership to 289,461 shares valued at approximately $741,000 [1] Product Development - Protalix is expanding its ProCellEx platform into drug delivery optimization, targeting specific tissue requirements, which is considered a "game-changer" for the company [3] - The ProCellEx platform is noted for its cost efficiency and ability to express complex protein capabilities, positioning it as a leader in future biopharmaceutical developments [3] Market Position - The company is recognized as a hidden penny stock with potential for growth, likened to planting a tree that requires time and patience to flourish [2]

Company Overview - Protalix BioTherapeutics (PLX) is a commercial-stage biotech company focused on recombinant therapeutic proteins [1] - The company utilizes its proprietary plant cell-based ProCellEx technology [1] Product Portfolio - Protalix has two approved enzyme replacement therapies: 1) Elfabrio for Fabry disease 2) Elelyso for Gaucher disease [1]

Company Overview - Protalix BioTherapeutics (PLX) is a biotechnology company that has two marketed therapies: Elelyso for Gaucher disease and Elfabrio for Fabry Disease [1] - The company is actively developing a clinical pipeline that may present future opportunities [1] Market Position - The presence of two marketed therapies positions Protalix BioTherapeutics as a player in the biotechnology sector focused on rare diseases [1]